UUUP she goes again.. FDA DECISION ON APRIL 1 M
Post# of 83
FDA DECISION ON APRIL 1 Migraine Drug + Cannabis drugs launch in 2H19 = 1000%++ UPSIDE POTENTIAL on this one
IGXT = Marketcap $57 M // Cash $13 M or 2 years of Cash //FDA DECISION on APRIL 1 (migraine Drug) // 3 Drugs awaitng FDA approval // Another 8 Drugs in late stage including a potential Blockbuster for Alzheimer with Phase 2 results expected this year and Cannabis Drugs partnered with TILRAY (TLRY) Market launch for the cannabis drugs in 2H 2019 = 10+ Bagger Play ,get some before FDA run up starts...glta
IntelGenx Corp. (OTCQX: IGXT) today announced that its 505(b)(2) New Drug Application resubmission for RIZAPORT® oral soluble film 10 mg for the treatment of acute migraines has been accepted for review by the U.S. Food and Drug Administration .The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date for completion of the review of the RIZAPORT® NDA of April 1, 2019.
IntelGenx and Tilray on go with Q4 launch of cannabis-infused oral film
http://www.biotuesdays.com/briefs/2019/1/14/i...-late-2019